Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.
Profitability
This table compares Akebia Therapeutics and ProMIS Neurosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akebia Therapeutics | -22.99% | N/A | -18.01% |
| ProMIS Neurosciences | N/A | -2,311.60% | -130.13% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Akebia Therapeutics and ProMIS Neurosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akebia Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| ProMIS Neurosciences | 0 | 0 | 2 | 0 | 3.00 |
Volatility & Risk
Akebia Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Insider & Institutional Ownership
33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 3.8% of Akebia Therapeutics shares are held by insiders. Comparatively, 10.3% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Akebia Therapeutics and ProMIS Neurosciences’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akebia Therapeutics | $194.62 million | 1.18 | -$51.92 million | ($0.23) | -4.78 |
| ProMIS Neurosciences | $10,000.00 | 3,308.52 | -$13.21 million | ($0.74) | -2.36 |
ProMIS Neurosciences has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than ProMIS Neurosciences, indicating that it is currently the more affordable of the two stocks.
Summary
ProMIS Neurosciences beats Akebia Therapeutics on 7 of the 13 factors compared between the two stocks.
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
